Sugi Predict

Sugi Predict / Compounds / SCHEMBL247552

SCHEMBL247552

SCHEMBL247552

COC(=O)C(NC(=O)OC(C)(C)C)C(C)C

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.55
▸ CTSS P25774 2/20 0.55
▸ CA2 P00918 2/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA7 P43166 1/20 0.51
▸ PSENEN Q9NZ42 1/20 0.51
▸ KLK5 Q9Y337 1/20 0.51
▸ PREP P48147 1/20 0.48
▸ CA12 O43570 2/20 0.47
▸ CA14 Q9ULX7 2/20 0.47
▸ TRPA1 O75762 2/20 0.47
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ CYP2D6 P10635 1/20 0.46
▸ TSHR P16473 1/20 0.41
▸ TAS1R3 Q7RTX0 1/20 0.41
▸ TAS1R1 Q7RTX1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8807250 1.00 CTSK (0.55) CTSKCTSSCA2CA1CA7
SCHEMBL1505521 1.00 CTSK (0.55) CTSKCTSSCA2CA1CA7
SCHEMBL7104010 0.93 PSENEN (0.59) CTSKCTSSCA2CA1CA7
SCHEMBL17137934 0.93 PSENEN (0.59) CTSKCTSSCA2CA1CA7
SCHEMBL2548149 0.93 PSENEN (0.59) CTSKCTSSCA2CA1CA7
SCHEMBL23260554 0.90 CTSK (0.57) CTSKCTSSCA2CA1CA7
SCHEMBL9727285 0.89 CTSK (0.55) CTSKCTSSCA2CA1CA7
SCHEMBL30698086 0.88 PSENEN (0.52) CTSKCTSSCA2CA1CA7
SCHEMBL30698103 0.88 PSENEN (0.52) CTSKCTSSCA2CA1CA7
SCHEMBL30698109 0.88 PSENEN (0.52) CTSKCTSSCA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12221459-B2 Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides MEDIVIR AB (SE) 2025-02-11 — — US disclosed
WO-2023196614-A1 METHODS AND COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS AXONIS THERAPEUTICS, INC. (US) 2023-10-12 — — WO disclosed
CN-112262145-B 2-aminopyrimidine derivative and preparation method and application thereof 上海奕拓医药科技有限责任公司 2023-08-01 — — CN disclosed
US-20230149500-A1 SMAC MIMETIC MEDIVIR AB (SE) 2023-05-18 — — US disclosed
US-20220226298-A1 GPR40 AGONISTS KALLYOPE, INC. 2022-07-21 — — US disclosed
EP-3976576-A1 GPR40 AGONISTS Kallyope, Inc. (US) 2022-04-06 — — EP disclosed
US-11207323-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-12-28 — — US disclosed
CN-113166173-A Spiro-sulfonamide derivatives as inhibitors of myeloid leukemia 1(MCL-1) protein 普莱鲁德疗法有限公司 2021-07-23 — — CN disclosed
US-20200316065-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2020-10-08 — — US disclosed
US-10639308-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2020-05-05 — — US disclosed
EP-2178869-A1 INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG Life Sciences Ltd. (KR) 2010-04-28 — — EP disclosed
WO-2009106885-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 ASTRAZENECA AB (SE) 2009-09-03 — — WO disclosed
WO-2009025477-A1 INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG LIFE SCIENCES LTD. (KR) 2009-02-26 — — WO disclosed
CN-1304380-C Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LTD (GB) 2007-03-14 — — CN disclosed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 — — US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 — — US disclosed
CN-1433406-A Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors XENOVA LTD (GB) 2003-07-30 — — CN disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 — — US disclosed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 — — EP disclosed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220226298-A1 GPR40 AGONISTS GPR119, GPR65, GLP1R CTSK 4230/4885CTSS 3739/4885CA2 4506/4885
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A CTSK 3439/4885CTSS 3151/4885CA2 1019/4885
US-11207323-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885CA2 1774/4885
US-10639308-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885CA2 1774/4885
US-12221459-B2 Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides PNP, NUDT1, TYMP CTSK 3925/4885CTSS 2840/4885CA2 2702/4885
US-20230149500-A1 SMAC MIMETIC SMARCC1, SMARCC2, MCL1 CTSK 3104/4885CTSS 3508/4885CA2 4509/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B CTSK 3950/4885CTSS 3181/4885CA2 302/4885
US-20200316065-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885CA2 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.